Publication: The efficacy and safety of lyophilized cryoprecipitate in hemophilia A
Issued Date
1999-12-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0042211211
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999)
Suggested Citation
Ampaiwan Chuansumrit, Parttraporn Isarangkura, Aroonrat Chantanakajornfung, Kesanee Kuhathong, Pakaimas Pintadit, Chattaya Jitpraphai, Phongjan Hathirat, Chaivej Nuchprayoon The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25548
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The efficacy and safety of lyophilized cryoprecipitate in hemophilia A
Other Contributor(s)
Abstract
This prospective study of assessing the efficacy and safety of lyophilized cryoprecipitate (LC), which was heat-treated at 60°C for 25 hours, was conducted in 23 patients with hemophilia A (severe 13, moderate 9, mild 1) at the International Hemophilia Training Center, Bangkok from 1997 to 1998. A total of 223 infusions of LC were given. The status of the patients could be classified into 4 groups : group I, non-bleeding (n = 13); group II, severe bleeding requiring hospitalization (n = 9); group III, appendectomy (n = 1) and group IV, early bleeding controlled by modified home treatment (n = 200). Pharmacokinetic studies were conducted in groups I and II. The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean in vivo incremental recovery at baseline was 2.1 per cent/unit/kg. The mean clearance was 3.22 ml/kg/h. There was no statistically significant difference in these parameters between groups I and II (p > 0.05). The hemostasis was successfully achieved and 1 to 2 small urticarial wheals were observed in only 2 infusions. In addition, 9 out of 23 patients received LC exclusively for 1 year. None of them developed inhibitor to F VIII:C nor did any contract additional transfusion-transmitted infection except one who developed anti-hepatitis C virus seroconversion after receiving 16 bottles of LC in 4 months. Therefore, the more efficient virus-inactivation in the preparation of LC should be established.